NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.

[NextPoint Therapeutics @NextPointTX]

NextPoint CMO Leena Gandhi, MD, PhD, will attend #ESMO2026 in Madrid, October 23–27. We look forward to discussing our B7-H7-targeted pipeline, including T cell engagers, ADCs and checkpoint inhibitors, and connecting with the oncology community.

[NextPoint Therapeutics @NextPointTX]

NextPoint Therapeutics CEO Ivan Cheung will attend the Goldman Sachs Healthcare Private Company Conference on October 19 in NYC.

Attending? Connect with Ivan to learn more about our approach to developing novel cancer immunotherapies targeting B7-H7. #ImmunoOncology

[NextPoint Therapeutics @NextPointTX]

NextPoint will participate in the Needham Private Biotech & MedTech Virtual 1×1 Forum, Oct. 13–14.
CEO Ivan Cheung looks forward to connecting with investors and sharing updates on NextPoint.
Interested in meeting with Ivan? Please reach out!

[NextPoint Therapeutics @NextPointTX]

NextPoint CSO Tatiana Novobrantseva, Ph.D., will be speaking at the World Bispecific Summit with an Industry Leaders Panel, followed by a presentation on NextPoint’s approach to B7-H7 and the development of NPX372. Attending? Let's connect! #WorldBispecificSummit

[NextPoint Therapeutics @NextPointTX]

Executive Director
Matthew Rausch, PhD, is presenting a poster atSITC Spring Scientific meeting. The poster explores the biology of the B7-H7 pathway and its potential to enhance T-cell–mediated anti-tumor responses. Reach out if you want to connect! #SITC

[NextPoint Therapeutics @NextPointTX]

#InternationalWomensDay may have passed, but we’re still celebrating the women whose expertise and leadership drive our work at NextPoint. A snapshot of the people behind the science advancing precision immuno-oncology.
#WomenInScience #WomenInBiotech

[NextPoint Therapeutics @NextPointTX]

In Scrip’s “What Does 2026 Hold for Biopharma?” outlook, Tatiana Novobrantseva, CSO of NextPoint Therapeutics, shares her view on where oncology differentiation is headed, novel targets, deep biology, and modality-agnostic precision.

Read more: https://t.co/aSVg2KHAmg

[NextPoint Therapeutics @NextPointTX]

Clinical entry of NPX372, a first-in-class B7-H7–targeted T cell engager, following U.S. IND clearance.

The first-in-human study pairs an IgG-like CD3 bispecific with biomarker-driven patient selection to enable rapid clinical readouts in solid tumors.
https://t.co/387iPsgvDA

[NextPoint Therapeutics @NextPointTX]

A look at CEO Ivan Cheung presenting at the JP Morgan Conference. Ivan shared our precision oncology strategy across T cell engager, ADC and checkpoint inhibitor, grounded in B7-H7 science and biomarker-driven patient selection. Energized by conversations and year ahead.

[NextPoint Therapeutics @NextPointTX]

Jamie Strand, Ph.D., VP of Technical Operations, will speak at the CMC Strategy Forum North America on Jan 26, sharing how protein engineering and CMC-driven cell-line development support consistent, manufacturable B7-H7 biologics ready for the clinic. #CASSS #CMCNA2026

[NextPoint Therapeutics @NextPointTX]

Ivan Cheung, CEO of NextPoint Therapeutics, will present at the 2026 J.P. Morgan Healthcare Conference on Jan 15 at 8:30 am in San Francisco. NextPoint is advancing precision therapeutics across multiple modalities targeting B7-H7. 
#JPM2026

[NextPoint Therapeutics @NextPointTX]

Data from NextPoint Therapeutics at #AACR-NCI-EORTC!

NPX125, a B7-H7–targeting ADC, shows potent anti-tumor activity across solid tumor models.
Reinforcing the promise of B7-H7 as a next-generation ADC target.

[NextPoint Therapeutics @NextPointTX]

Headed to AACR-NCI-EORTC! Sr. Scientist Emilien Loeuillard will present a poster on NPX125, our novel ADC targeting B7-H7, a molecule central to tumor immune escape and highly expressed in tumors.

[NextPoint Therapeutics @NextPointTX]

Join NextPoint Chief Scientific Officer Tatiana Novobrantseva and Director, Research and Development Melissa Hayes, at #SITC25 where they will be presenting the poster:
TMIGD2 co-stimulation in a trispecific T cell engager elicits potent anti-tumor activity.

[NextPoint Therapeutics @NextPointTX]

Heading to the ADC Linker & Conjugation Summit? Catch NextPoint CSO Tatiana Novobrantseva, PhD, on Aug 20 as she shares unique attributes of NPX125, a DAR8 B7-H7 targeting ADC with a novel linker.

Can't make it? Let's connect!

[NextPoint Therapeutics @NextPointTX]

NextPoint CSO Tatiana Novobrantseva, PhD, will moderate a plenary panel at the #IOSummit on Aug 13: "Accelerating IO through Target Discovery." Proud to see B7-H7 biology and smart target selection front and center in solid tumor IO.

[NextPoint Therapeutics @NextPointTX]

NextPoint VP of Innovation Bijan Etemad-Gilbertson is heading to #BIO2025. We're advancing first-in-class precision therapeutic targeting the B7-H7 axis. Let’s connect in Boston to talk ADCs, TCEs & more.

[NextPoint Therapeutics @NextPointTX]

CSO Tatiana Novobrantseva is featured in Databird’s “30 Visioneers Shaping the Future of Biotech in 2025.” She shares how NextPoint’s B7-H7 pathway approach offers a new angle on immune activation beyond PD-L1.
Read more: https://t.co/36fWmHvbpX

[NextPoint Therapeutics @NextPointTX]

CMO Dr. Leena Gandhi, MD, PhD, speaks at Stanford's Stat4Onc Symposium on “Maintaining Flexibility in Dose Optimization in Early Phase Oncology Trials.” Don’t miss this expert-packed session on dose optimization across the drug lifecycle! #Stat4Onc #OncologyTrials

[NextPoint Therapeutics @NextPointTX]

#AACR2025 Recap: B7-H7-ADC NPX125
✅ Tumor-selective
✅Minimal normal tissue
✅High receptor density
Strong interest in NPX125’s targeting & proprietary linker tech.